Zur Kurzanzeige

Botulinumtoxin-Typ A - eine Therapieoption bei überaktiven und nicht-neurogenen Blasenentleerungsstörungen (retrospektive Datenanalyse)

dc.contributor.advisorLoertzer, Hagen PD Dr.de
dc.contributor.authorZachert, Katharinade
dc.date.accessioned2013-01-20T13:04:40Zde
dc.date.available2013-01-30T23:51:04Zde
dc.date.issued2009-11-11de
dc.identifier.urihttp://hdl.handle.net/11858/00-1735-0000-000D-F0DD-Ede
dc.identifier.urihttp://dx.doi.org/10.53846/goediss-3346
dc.format.mimetypeapplication/pdfde
dc.language.isogerde
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/de
dc.titleBotulinumtoxin-Typ A - eine Therapieoption bei überaktiven und nicht-neurogenen Blasenentleerungsstörungen (retrospektive Datenanalyse)de
dc.typedoctoralThesisde
dc.title.translatedBotulinum toxin type A - a treatment option for overactive and non-neurogenic detrusor overactivity (retrospective study)de
dc.contributor.refereeLoertzer, Hagen PD Dr.de
dc.date.examination2010-01-10de
dc.subject.dnb610 Medizin, Gesundheitde
dc.subject.gokMED 471de
dc.description.abstractengObjectives: Since the first therapeutic applications of botulinum toxin about 20 years ago, it has become an effective treatment for various indications including overactive and non-neurogenic detrusor overactivity. Synthesized in Clostridium botulinum, the neurotoxin inhibits the acetylcholine secretion leading to a paralysis when injected into the detrusor muscle with both urodynamic and clinical improvements. This minimally invasive treatment is positioned between ineffective anticholinergic treatment and invasive surgery. The present retrospective study examined the effectiveness of transurethral injections of botulinum toxin given in the Department of Urology, University of Goettingen. Methods: Patients (n=32) with overactive and non-neurogenic detrusor overactivity received 88 injections of botulinum toxin type A in 13 injection cycles from February 2002 until October 2008. The effects on urodynamic and clinical parameters were analyzed. Also four injection protocols for future applications were created. Results: In most cases 300 units of Botoxde
dc.subject.topicMedicinede
dc.subject.gerBotulinumtoxin-Typ Ade
dc.subject.gerBlasenentleerungsstörungende
dc.subject.gerurodynamische Parameterde
dc.subject.engBotulinum toxin type Ade
dc.subject.engdetrusor overactivityde
dc.subject.engurodynamic parametersde
dc.subject.bk44.88de
dc.identifier.urnurn:nbn:de:gbv:7-webdoc-2262-9de
dc.identifier.purlwebdoc-2262de
dc.affiliation.instituteMedizinische Fakultätde
dc.identifier.ppn635339862de


Dateien

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige